Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Tatos Akopian"'
Autor:
Harim I. Won, Samuel Zinga, Olga Kandror, Tatos Akopian, Ian D. Wolf, Jessica T. P. Schweber, Ernst W. Schmid, Michael C. Chao, Maya Waldor, Eric J. Rubin, Junhao Zhu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract Proteolysis-targeting chimeras (PROTACs) represent a new therapeutic modality involving selectively directing disease-causing proteins for degradation through proteolytic systems. Our ability to exploit targeted protein degradation (TPD) for
Externí odkaz:
https://doaj.org/article/b9ac70b36b4b4800bd5cfffe2f4e65d9
Autor:
Pooja Gopal, Jickky Palmae Sarathy, Michelle Yee, Priya Ragunathan, Joon Shin, Shashi Bhushan, Junhao Zhu, Tatos Akopian, Olga Kandror, Teck Kwang Lim, Martin Gengenbacher, Qingsong Lin, Eric J. Rubin, Gerhard Grüber, Thomas Dick
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
It has been shown that the bioactive component of pyrazinamide, pyrazinoic acid (POA), blocks coenzyme A biosynthesis in M. tuberculosis by binding to the aspartate decarboxylase PanD. Here the authors show that pyrazinamide triggers degradation of P
Externí odkaz:
https://doaj.org/article/840f3d486eeb4f43af457982724b4b9d
Autor:
Harim I. Won, Junhao Zhu, Olga Kandror, Tatos Akopian, Ian D. Wolf, Michael C. Chao, Maya Waldor, Eric J. Rubin
Proteolysis-targeting chimeras (PROTACs) represent a new therapeutic modality involving selectively directing disease-causing proteins for degradation through proteolytic systems. Our ability to exploit this targeted protein degradation (TPD) approac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44f587f1cea4bfa5f269a83d7d337acd
https://doi.org/10.1101/2023.02.14.528552
https://doi.org/10.1101/2023.02.14.528552
Autor:
Seungpyo Hong, Ying Yu Jin, Joo Won Suh, Seung Hwan Yang, Tae Mi Yoon, Suhair Sunoqrot, Sang-Hyun Cho, Wei Gao, Surafel Mulugeta, Tatos Akopian, Scott G. Franzblau, Jin Yong Kim, Sun-Young Lee, Yuehong Wang, In Ae Lee, Guido F. Pauli, Alfred L. Goldberg, Olga Kandror, Jong Woo Kim, Jeffrey R. Anderson, James B. McAlpine
Drug-resistant tuberculosis (TB) has lent urgency to finding new drug leads with novel modes of action. A high-throughput screening campaign of >65,000 actinomycete extracts for inhibition of Mycobacterium tuberculosis viability identified ecumicin,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c518037088517d3781eef110a3f88b
Autor:
Tatos Akopian, Junhao Zhu, Michael R. Chase, Olga Kandror, Jemila C. Kester, Alfred L. Goldberg, Eric J. Rubin, Sarah M. Fortune
Publikováno v:
Journal of Bacteriology
Tuberculosis, caused by Mycobacterium tuberculosis, imposes a major global health burden, surpassing HIV and malaria in annual deaths. The ClpP1P2 proteolytic complex and its cofactor ClpX are attractive drug targets, but their precise cellular funct
Autor:
Martin Gengenbacher, Tatos Akopian, Olga Kandror, Thomas Dick, Gerhard Grüber, Priya Ragunathan, Jickky Palmae Sarathy, Michelle Yee, Junhao Zhu, Qingsong Lin, Pooja Gopal, Teck Kwang Lim, Shashi Bhushan, Eric J. Rubin, Joon Shin
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-10 (2020)
Nature Communications
Nature Communications
Pyrazinamide is a sterilizing first-line tuberculosis drug. Genetic, metabolomic and biophysical analyses previously demonstrated that pyrazinoic acid, the bioactive form of the prodrug pyrazinamide (PZA), interrupts biosynthesis of coenzyme A in Myc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fedaab382d6efd481e1166129bf1960
https://hdl.handle.net/10356/138824
https://hdl.handle.net/10356/138824
Autor:
Ravikiran M. Raju, Tatos Akopian, D. Branch Moody, Johannes Lehmann, Annie S. Park, Eric J. Rubin, Evelyn Zeiler, James C. Sacchettini, Stephan A. Sieber, Tan-Yun Cheng, Anup Aggarwal, Olga Kandror
Publikováno v:
Angewandte Chemie. 130:354-359
Autor:
Beatriz Rodriguez, Tatos Akopian, Gonzalo Colmenarejo, Ana I. Bardera, Joël Lelièvre, Concha Cid, Annie Park, Alfred L. Goldberg, Olga Kandror, Hugo Pacheco de Freitas Fraga
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Tuberculosis affects about 100 million people worldwide and causes nearly 2 million deaths annually. It has been estimated that one third of all humans is infected with latent Mycobacterium tuberculosis (Mtb). Moreover, Mtb has become increasingly re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cf9c71194f17e8d01bfce1d7876f7d1
https://europepmc.org/articles/PMC6484444/
https://europepmc.org/articles/PMC6484444/
Autor:
Alexander Wlodawer, Mi Li, Poorva Dharkar, Alfred L. Goldberg, Olga Kandror, Tatos Akopian, Michael R. Maurizi
Publikováno v:
Journal of Biological Chemistry. 291:7465-7476
The ClpP protease complex and its regulatory ATPases, ClpC1 and ClpX, in Mycobacterium tuberculosis (Mtb) are essential and, therefore, promising drug targets. The Mtb ClpP protease consists of two heptameric rings, one composed of ClpP1 and the othe
Autor:
Evelyn Zeiler, Anup Aggarwal, James C. Sacchettini, Stephan A. Sieber, Eric J. Rubin, Ravikiran M. Raju, Olga Kandror, Tan-Yun Cheng, Tatos Akopian, Johannes Lehmann, D. Branch Moody, Annie S. Park
The spread of antibiotic resistance is a major challenge for treatment of Mycobacterium tuberculosis infection. In addition, efficacy of drugs is often limited by the restricted permeability of the mycomembrane. Frontline antibiotics inhibit mycomemb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98fe58656ebc7c3b5f3ed07c53b863fb
https://europepmc.org/articles/PMC6104829/
https://europepmc.org/articles/PMC6104829/